NASDAQ · RPRX
Royalty Pharma plc
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for RPRX: Nov 04, 2026
Royalty Pharma plc Class A Ordinary Shares is expected to report earnings on 11/04/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $1.18. The reported EPS for the same quarter last year was $1.17.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $1.18 | $1.21 | $1.15 | 4 |
| Dec 2026 | $1.53 | $1.54 | $1.52 | 3 |
| Mar 2027 | $0.78 | $0.78 | $0.78 | 1 |
| Jun 2027 | $0.32 | $0.32 | $0.32 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · The Motley Fool · MarketBeat- Zacks · Oct 30, 8:15 AM EDTUnveiling Royalty Pharma (RPRX) Q3 Outlook: Wall Street Estimates for Key MetricsBeyond analysts' top-and-bottom-line estimates for Royalty Pharma (RPRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2026.
- The Motley Fool · Oct 29, 9:50 AM EDTShould You Buy Royalty Pharma Stock Before Nov. 4?Royalty Pharma shares have surged ahead of the biotech funding company's Nov. 4 quarterly earnings release.
- Zacks · Oct 29, 9:00 AM EDTGuardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseGuardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 28, 9:00 AM EDTRoyalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseRoyalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- The Motley Fool · Oct 25, 10:35 AM EDTForget Biotech's Binary Bets: This Dividend Stock Collects Royalties on Blockbusters InsteadRoyalty Pharma is not a drug maker.
- The Motley Fool · Oct 22, 10:35 AM EDT3 Reasons Royalty Pharma Is a Dividend Stock You Never Have to SellRoyalty Pharma buys drug royalties.
- Zacks · Oct 8, 11:10 AM EDTWhy Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates AgainRoyalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- The Motley Fool · Oct 1, 12:50 PM EDTRoyalty Pharma Owns a Piece of 16 Blockbuster Drugs — Is the Stock a Buy?Royalty Pharma offers exposure to a diversified portfolio of promising drug products and candidates.
- Zacks · Sep 28, 7:55 AM EDTWant Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat EarningsFinding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
- MarketBeat · Sep 25, 2:02 AM EDTRoyalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy ShiftsHow Royalty Pharma Prints Cash Without Biotech's Biggest RisksRoyalty Pharma (NASDAQ:RPRX) executives said the company is monitoring a shifting biopharma policy environment, expanding its artificial-intelligence capabilities and building a presence in China, while maintaining a d
- The Motley Fool · Sep 24, 10:35 PM EDTIs Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?Revolution Medicines has just received good news around a drug meant to treat pancreatic cancer.
- Zacks · Sep 9, 3:54 PM EDTIs Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?Here is how Amarin (AMRN) and Royalty Pharma (RPRX) have performed compared to their sector so far this year.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Royalty Pharma plc from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.